These authors employed novel tau polyclonal antibodies to investigate tau pathology in 10 patients with clinically and pathologically confirmed Amyotrophic Lateral Sclerosis (ALS) (aka MND). The gene discussed is MAPT; the disease is amyotrophic lateral sclerosis.